

ASX ANNOUNCEMENT

CELLMID'S EUROPEAN MIDKINE PATENT FOR ALOPECIA ALLOWED

- **Patent for midkine treatment of alopecia allowed by European Patent Office**
- **Adding to the allowance by the US PTO last week of the same patent family**
- **Comprehensive protection over midkine for the prevention or reversal of hair loss**

SYDNEY: Tuesday, 7 FEBRUARY 2017, Cellmid Limited (ASX: CDY) is pleased to advise that, following the allowance by the US Patent and Trademark Office last week, the European Patent Office has issued Notice of Allowance for the patent application number 11746751.4 entitled "Method of Treatment or Prevention of Hair Loss or for Enhancement of Hair Growth" (midkine or MK alopecia patent).

The European midkine alopecia patent will expire in February 2031 and it adds to other allowances in the USA, Japan, Australia and UK for the same patent family. The patents represent not only significant intellectual property rights, but also opportunities for Advangen Limited, Cellmid's wholly owned subsidiary engaged in the development and commercialisation of hair loss technologies.

Interested investors should review Cellmid's announcement to the ASX dated 31 January 2017 for further details on the relevance of the patent family, however the results presented in the current patent are particularly relevant to hair loss caused by chemotherapy agents.

End

Contact: Maria Halasz, CEO

T +612 9221 6830

 @mariahalsz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lynamid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. Intellectual property pertaining to this novel target is being exploited through wholly owned subsidiaries Lynamid and Kinera. Advangen, Cellmid's consumer health business, sells its FGF5 inhibitor hair growth products in Australia and Japan, and currently expanding distribution in other territories. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au.

Midkine (MK)

Midkine is a growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, midkine is only evident in a disease context, and targeting midkine is not expected to harm normal healthy tissues.

Investment in life sciences companies

There are a number of inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Cellmid recommends that investors seek professional advice before making an investment in its shares.